Sana Biotechnology 3Q 2026: EPS $0.07 — 10-Q Summary

Sana Biotechnology reported a quarterly profit after a year-earlier loss, as a $63.4 million gain from changes in the fair value of success payment and contingent consideration liabilities—primarily reflecting an August amendment to the Cobalt acquisition agreement—more than offset higher research…